Expert Interview
Reviewing Arvinas' ARV-471 as a monotherapy protein degrader in ER+/HER2- Advanced Breast Cancer
Ticker(s): ARVN- Professor of Medicine major US academic medical center, Associate Division Chief for the Division of Hematology/Oncology, Medical Director of the Women's Cancer Program, & Associate Director for Clinical Investigations.
- Treats 750 patients with breast cancer.
- Principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program.
Please describe your background and practice setting.
Added By: ben_adminHow many patients with ER+/HER2- Advanced Breast Cancer do you manage?
Added By: ben_adminWhat is the standard of care for these patients?
Added By: ben_adminWhat are your thoughts on protein degradation as a target for breast cancer?
Added By: ben_adminWhat do you think of the ARV-471 trial results?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
